SE505938C2 - Protoporfyrinogen inhibitorer och användning därav i kompositioner för att detektera och behandla tumörer - Google Patents

Protoporfyrinogen inhibitorer och användning därav i kompositioner för att detektera och behandla tumörer

Info

Publication number
SE505938C2
SE505938C2 SE9101807A SE9101807A SE505938C2 SE 505938 C2 SE505938 C2 SE 505938C2 SE 9101807 A SE9101807 A SE 9101807A SE 9101807 A SE9101807 A SE 9101807A SE 505938 C2 SE505938 C2 SE 505938C2
Authority
SE
Sweden
Prior art keywords
inhibitor
protoporphyrinogen
compound
protoporphyrin
protoporphyrinogen oxidase
Prior art date
Application number
SE9101807A
Other languages
English (en)
Swedish (sv)
Other versions
SE9101807D0 (sv
SE9101807L (sv
Inventor
Blaik Phillip Halling
Debra Ann Witkowski
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of SE9101807D0 publication Critical patent/SE9101807D0/xx
Publication of SE9101807L publication Critical patent/SE9101807L/xx
Publication of SE505938C2 publication Critical patent/SE505938C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SE9101807A 1988-12-12 1991-06-12 Protoporfyrinogen inhibitorer och användning därav i kompositioner för att detektera och behandla tumörer SE505938C2 (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28515188A 1988-12-12 1988-12-12
US33500789A 1989-04-07 1989-04-07
US35133189A 1989-05-03 1989-05-03
PCT/US1989/005599 WO1990006748A2 (en) 1988-12-12 1989-12-08 Use of certain herbicides in cancer treatment and production of protoporphyrin ix

Publications (3)

Publication Number Publication Date
SE9101807D0 SE9101807D0 (sv) 1991-06-12
SE9101807L SE9101807L (sv) 1991-06-12
SE505938C2 true SE505938C2 (sv) 1997-10-27

Family

ID=27403508

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101807A SE505938C2 (sv) 1988-12-12 1991-06-12 Protoporfyrinogen inhibitorer och användning därav i kompositioner för att detektera och behandla tumörer

Country Status (28)

Country Link
EP (1) EP0447491B1 (enExample)
JP (1) JP2545000B2 (enExample)
KR (1) KR930003116B1 (enExample)
AR (1) AR243605A1 (enExample)
AT (1) AT400520B (enExample)
AU (1) AU633537B2 (enExample)
BR (1) BR8907817A (enExample)
CA (1) CA2004979A1 (enExample)
CH (1) CH681779A5 (enExample)
DE (2) DE3991484T (enExample)
DK (1) DK110791A (enExample)
EG (1) EG18822A (enExample)
ES (1) ES2051675T3 (enExample)
FI (1) FI912784A0 (enExample)
GB (1) GB2247404B (enExample)
GR (1) GR1000609B (enExample)
HU (1) HUT58202A (enExample)
IE (1) IE62621B1 (enExample)
IL (1) IL92622A (enExample)
LU (1) LU87949A1 (enExample)
LV (1) LV10303B (enExample)
MC (1) MC2171A1 (enExample)
NO (1) NO912228L (enExample)
NZ (1) NZ231658A (enExample)
OA (1) OA09362A (enExample)
PT (1) PT92546B (enExample)
SE (1) SE505938C2 (enExample)
WO (1) WO1990006748A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298502A (en) * 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
US5132101A (en) * 1990-05-04 1992-07-21 Cytopharm, Inc. Acetylene-cumulene porphycene compounds for photodynamic therapy
US5244671A (en) * 1991-01-29 1993-09-14 Cytopharm, Inc. Derivatives of porphycene for photodynamic therapy of cancer
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
GB9318841D0 (en) * 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US6084155A (en) 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
HUP9900623A3 (en) * 1996-02-28 2001-11-28 Novartis Ag Promoters from plant protoporphyrinogen oxidase genes
JPH10330359A (ja) * 1997-03-31 1998-12-15 Nippon Bayeragrochem Kk フエニルアセチレン誘導体及び除草剤
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
SI2443102T1 (sl) 2009-06-19 2013-08-30 Basf Se Herbicidni benzoksazinoni
US8445407B2 (en) * 2009-11-02 2013-05-21 Basf Se Herbicidal tetrahydrophthalimides
CN103221409B (zh) * 2010-10-01 2016-03-09 巴斯夫欧洲公司 除草的苯并*嗪酮类
US8916501B2 (en) 2010-12-15 2014-12-23 Basf Se Herbicidal compositions
CN102875569A (zh) * 2012-09-27 2013-01-16 南开大学 具有除草活性和抗肝癌活性的异噁唑并嘧啶酮(或三嗪酮)类化合物
AU2017375394B2 (en) * 2016-12-16 2021-10-21 Basf Se Herbicidal phenyltriazolinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393071A (en) * 1975-03-17 1983-07-12 Naoharu Fujii Method of treating gastric, mammary, lung and uterus tumors
US4404019A (en) * 1980-12-24 1983-09-13 Sumitomo Chemical Company, Limited 3-Chloro-1-phenyl-1,2,4-triazolin-5-ones and their use as herbicides
CH651029A5 (de) * 1980-12-25 1985-08-30 Nihon Nohyaku Co Ltd Triazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel.
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4755217A (en) * 1987-01-15 1988-07-05 Fmc Corporation Triazinedione herbicides
US4761174A (en) * 1987-04-14 1988-08-02 Fmc Corporation Triazolin-5-one herbicides

Also Published As

Publication number Publication date
LU87949A1 (fr) 1991-12-16
LV10303B (en) 1995-08-20
LV10303A (lv) 1994-10-20
KR930003116B1 (ko) 1993-04-19
PT92546B (pt) 1995-09-12
CH681779A5 (enExample) 1993-05-28
SE9101807D0 (sv) 1991-06-12
EP0447491B1 (en) 1993-08-11
DK110791D0 (da) 1991-06-11
AR243605A1 (es) 1993-08-31
EG18822A (en) 1994-09-29
AU633537B2 (en) 1993-02-04
CA2004979A1 (en) 1990-06-12
JP2545000B2 (ja) 1996-10-16
JPH04501420A (ja) 1992-03-12
HUT58202A (en) 1992-02-28
WO1990006748A2 (en) 1990-06-28
EP0447491A1 (en) 1991-09-25
DE3991484C2 (de) 1995-02-23
GR890100817A (en) 1991-03-15
KR910700046A (ko) 1991-03-13
NO912228D0 (no) 1991-06-11
MC2171A1 (fr) 1992-05-22
AU4822290A (en) 1990-07-10
IL92622A (en) 1996-05-14
BR8907817A (pt) 1991-10-22
IE893925L (en) 1990-06-12
NO912228L (no) 1991-06-11
FI912784A7 (fi) 1991-06-10
ES2051675T1 (es) 1994-07-01
DK110791A (da) 1991-08-12
GB2247404B (en) 1993-03-03
OA09362A (en) 1992-09-15
WO1990006748A3 (en) 1990-10-04
DE3991484T (enExample) 1991-11-21
ATA903489A (de) 1995-06-15
GB2247404A (en) 1992-03-04
AT400520B (de) 1996-01-25
GB9110472D0 (en) 1991-11-27
IE62621B1 (en) 1995-02-22
FI912784A0 (fi) 1991-06-10
PT92546A (pt) 1990-06-29
NZ231658A (en) 1992-05-26
GR1000609B (el) 1992-08-31
SE9101807L (sv) 1991-06-12
IL92622A0 (en) 1990-08-31
ES2051675T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
US5407808A (en) Method and composition for photodynamic treatment and detection of tumors
US5298502A (en) Method and composition for photodynamic treatment and detection of tumors
AT400520B (de) Protoporphyrinogeninhibitoren und deren verwendung in zusammensetzungen zur erkennung und behandlung von tumoren
Subash et al. Morin a flavonoid exerts antioxidant potential in chronic hyperammonemic rats: a biochemical and histopathological study
Subapriya et al. Ethanolic neem leaf extract protects against N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in Wistar rats
US4898878A (en) Antioxidant thiohistidine compounds
Eisler Paraquat hazards to fish, wildlife, and invertebrates: a synoptic review
US5849748A (en) Therapeutic quassinoid preparations with antineoplastic antiviral, and herbistatic activity
AP76A (en) Porphyric Insecticides
Plaine et al. Influence of tryptophan and related compounds upon the action of a specific gene and the induction of melanotic tumours in Drosophila Melanogaster: With two text-figures
Sancho et al. Effects of sublethal exposure to a pesticide on levels of energetic compounds in Anguilla anguilla.
Velmurugan et al. Effect of S-allylcysteine on oxidant-antioxidant status during N-methyl-N'-nitro-N-nitrosoguanidine and saturated sodium chloride-induced gastric carcinogenesis in Wistar rats
CS176291A3 (en) Pharmaceutical
KR19990071183A (ko) 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
HRP930762A2 (en) Preparation and use of porphyrin
Gardner et al. Inhibition of phytochrome synthesis by the transaminase inhibitor, 4-amino-5-fluoropentanoic acid
Aneja et al. Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male wistar rats
LT3997B (en) Process for preparing protoporphyrins and use thereof
Hikawa The mode of action of chlomethoxyfen
ITO et al. Studies on the Depressive Factors in Heterochordaria abietina Affecting the Blood Cholesterol Level in Rats II. Hypocholesterolemic Activity of Chlorophyll, Its Derivatives and Magnesium
Fukami Insecticides as inhibitors of respiration
Varior Biochemical and Histopathological effects of aflatoxin on Oreochromis mossambicus (Peters)
Hallahan The mode of action of nitrodiphenyl ether and related herbicides
Matsunaka History and early investigation of mode of action of peroxidizing herbicides
Goyal TOXICOLOGICAL, BIOCHEMICAL AND IMMUNO-PATHOLOGICAL EFFECTS OF THIACLOPRID IN GALLUS DOMESTICUS

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9101807-7

Format of ref document f/p: F